SJEPD030168_D1.RNA-Seq
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- age_years
- 4.39
- e1_e2
- E2
- umap1_2d
- -6.409745884
- umap2_2d
- 2.096169815
- umap1_3d
- -0.785682794
- umap2_3d
- 4.433091423
- umap3_3d
- -0.294884948
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.580
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.520
- PROTEIN_SECRETION+0.410
- OXIDATIVE_PHOSPHORYLATION+0.390
- MITOTIC_SPINDLE+0.330
- MTORC1_SIGNALING+0.300
- MYC_TARGETS_V2+0.300
- DNA_REPAIR+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.260
Top 10 suppressed
- MYOGENESIS-0.270
- PANCREAS_BETA_CELLS-0.250
- XENOBIOTIC_METABOLISM-0.250
- COAGULATION-0.210
- IL6_JAK_STAT3_SIGNALING-0.180
- APICAL_JUNCTION-0.170
- APICAL_SURFACE-0.170
- KRAS_SIGNALING_DN-0.170
- HEDGEHOG_SIGNALING-0.140
- CHOLESTEROL_HOMEOSTASIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030367_D1.RNA-Seq | EPN | Anaplastic EPN | 0.872 |
| 2 | E0DE33EA-C3DF-478E-9C4D-86E3C7B3A1D9 | — | — | 0.854 |
| 3 | C4A69C6F-E199-43CF-9DA1-94E1B3AE7388 | — | — | 0.852 |
| 4 | SRR934915 | — | — | 0.851 |
| 5 | 1FB9316D-4674-4D97-A33B-649F53D09487 | — | — | 0.850 |
| 6 | 8BC036E8-0EA0-4346-A551-2A5F8975FEAB | — | — | 0.844 |
| 7 | MDT-AP-2180 | Med | Medulloblastoma | 0.841 |
| 8 | BS_P7EY9DXG | ATRT | — | 0.841 |
| 9 | EE4F9349-F750-4471-BFE7-7230784569E1 | — | — | 0.839 |
| 10 | SRR934873 | — | — | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |